Drug discovery dilemma and Cura Quartet collaboration

Drug Discovery Today

Volumn 14, Issue 21-22, 2009, Pages 1006-1010

  Shah, Salim ^a   Federoff, Howard J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CLINICAL STUDY; DISEASE MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; GENETIC ENGINEERING; GOVERNMENT; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PHYLOGENY; PRACTICE GUIDELINE; PROGNOSIS; QUANTITATIVE TRAIT LOCUS; SHORT SURVEY; TROPICAL DISEASE; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG INDUSTRY; FOUNDATIONS; GOVERNMENT; HUMANS; REPRODUCIBILITY OF RESULTS; RESEARCH; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; UNIVERSITIES;

EID: 70350427662     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.09.007     Document Type: Short Survey

References (13)

1. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715. A review detailing the sources of attrition in the pharmaceutical industry
2. Kramer J.A., Sagartz J.E., and Morris D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6 (2007) 636-649
3. Lombardino J.G., and Lowe J.A. The role of the medicinal chemist in drug discovery? then and now. Nat. Rev. Drug Discov. 3 (2004) 853-862
4. Wiseman E.H., and Lombardino J.G. In: Bindra J.S., and Lednicer D. (Eds). Chronicles of Drug Discovery Ch 8 (1982), J. Wiley and Sons, Inc. 173-200. An account of the discovery of the novel anti-inflammatory drug piroxicam
5. Trouiller P., Olliaro E., Torreele J., Orbinski R., Laing N., and Ford Trouiller P. Drugs development for neglected diseases: a deficient market and a public health policy failure. Lancet 359 (2002) 2188-2194
6. Hughes B. Pharma pursues novel models for academic collaboration. Nat. Rev. Drug Discov. 7 (2008) 631-632
7. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 7 (2007) 645-658
8. Haberman A.B. Strategies to move beyond target validation. Gen. Eng. Biotech. News 25 (2005) 26
9. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
10. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69 (2001) 89-95
11. The Biomarkers Consortium. On the Critical Path of Drug Discovery. Clin. Pharmacol. Ther. 83 (2008) 361-364
12. Guidance for Industry, Investigators, and Reviewers. Exploratory IND Studies (2006), U.S. Department of Health and Human Services, FDA, CDER
13. Brewer G.J. Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required. J. Invest. Med. 54 (2006) 291-302